Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dual Incontinence Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health

NCT04001088
View directory record Official record
Conditions
Menopause
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Lallemand Health Solutions
Industry
Eligibility
40 Years to 59 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
5
States / cities
Lake Worth, Florida • Port Saint Lucie, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 10, 2026, 7:34 PM EDT
Not listed Phase 2Phase 3 Interventional

This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.

NCT00479596
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botox
Drug
Lead sponsor
Urological Sciences Research Foundation
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated May 29, 2007 · Synced Sep 10, 2026, 7:34 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.

NCT00323635
View directory record Official record
Conditions
Urinary Incontinence
Interventions
tolterodine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 10, 2026, 7:34 PM EDT
Terminated Phase 3 Interventional Results available

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

NCT02660138
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 10, 2026, 7:34 PM EDT
Completed Phase 4 Interventional

Detrol LA In Men With Overactive Bladder.

NCT00282932
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Detrol LA
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
11
States / cities
Anaheim, California • La Mesa, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 10, 2026, 7:34 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

NCT03052764
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence
Interventions
onabotulinumtoxinA, Placebo (saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Laguna Hills, California • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Sep 10, 2026, 7:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence

NCT01340066
View directory record Official record
Conditions
Urinary Incontinence
Interventions
UISH001, matching placebo
Drug
Lead sponsor
Beech Tree Labs, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Endwell, New York • Rochester, New York • Upper Saint Clair, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 10, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)

NCT04193176
View directory record Official record
Conditions
Chronic Cough
Interventions
Gefapixant, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Paramount, California • Jupiter, Florida • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 10, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency

NCT01294982
View directory record Official record
Conditions
Overactive Bladder
Interventions
AOBO-001, Placebo
Drug
Lead sponsor
American Oriental Bioengineering, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Mobile, Alabama • West Palm Beach, Florida • Newton, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 10, 2026, 7:34 PM EDT
Terminated Not applicable Interventional Results available

Sacral Neuromodulation in Dual Incontinence: Ultrasound and Afferent Nerve Sensation Assessment

NCT02357784
View directory record Official record
Conditions
Dual Incontinence, Fecal Incontinence, Urinary Incontinence, Sacral Neuromodulation
Interventions
Neurometer
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 10, 2026, 7:34 PM EDT
Completed Phase 4 Interventional Results available

A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

NCT00911937
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
112
States / cities
Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 10, 2026, 7:34 PM EDT
Terminated Phase 4 Interventional Results available

Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.

NCT02176642
View directory record Official record
Conditions
Urinary Urge Incontinence
Interventions
Oxybutynin extended release, Posterior Tibial Nerve Stimulation, Placebo
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 10, 2026, 7:34 PM EDT
Not listed Phase 3 Interventional

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

NCT01050114
View directory record Official record
Conditions
Overactive Bladder
Interventions
onaBoNT-A, Oxybutynin ER
Drug
Lead sponsor
Christopher Patrick Smith
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Sep 10, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

NCT06206512
View directory record Official record
Conditions
Heart Failure, Overactive Bladder, Incontinence
Interventions
Extended release torsemide, Immediate release torsemide, Extended release torsemide placebo, Immediate release torsemide placebo
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 10, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder

NCT00196404
View directory record Official record
Conditions
Urinary Incontinence
Interventions
DR-3001a, DR-3001b, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years and older · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
46
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2012 · Synced Sep 10, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

NCT00350636
View directory record Official record
Conditions
Overactive Bladder
Interventions
Oxybutynin topical gel, Placebo topical gel
Drug · Other
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Homewood, Alabama • Mobile, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated May 9, 2010 · Synced Sep 10, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

NCT03492281
View directory record Official record
Conditions
Overactive Bladder
Interventions
vibegron, Vibegron placebo, Tolterodine Tartrate ER, Tolterodine placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
191
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 155 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Sep 10, 2026, 7:34 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Nitrofurantoin and Urinary Tract Infections (UTIs)

NCT00678041
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Nitrofurantoin, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Sep 10, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

NCT01908829
View directory record Official record
Conditions
Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions
mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo
Drug
Lead sponsor
Astellas Pharma Europe Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 10, 2026, 7:34 PM EDT
Completed No phase listed Observational

Bladder Antimuscarinic Medication and Accidental Bowel Leakage

NCT03543566
View directory record Official record
Conditions
Urinary Incontinence, Urge, Fecal Incontinence
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 10, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

NCT03475706
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
86
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 10, 2026, 7:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence

NCT00345332
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Botox, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 90 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
3
States / cities
Sacramento, California • Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 10, 2026, 7:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does Treatment With Macrobid Reduce Urinary Tract Infections in Patients Receiving a Sub-Urethral Sling for Incontinence

NCT00734968
View directory record Official record
Conditions
Stress Incontinence
Interventions
Nitrofurantoin, Placebo
Drug · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Female only
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Sep 10, 2026, 7:34 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder

NCT00773552
View directory record Official record
Conditions
Urinary Urge, Urge Incontinence, Overactive Bladder
Interventions
solifenacin succinate, placebo
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
20 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 10, 2026, 7:34 PM EDT